Veradermics reports Phase 3 trial success for oral hair‑loss drug VDPHL01
Veradermics announced that its Phase 3 Study 304 of VDPHL01 in 536 male participants met all primary and secondary endpoints. The once‑daily dose increased target‑area hair count by 28.6 hairs/cm² and the twice‑daily dose by 36.4 hairs/cm², versus 6.6 hairs/cm² for placebo, with 78.8% and 85.0% of patients reporting improvement respectively. No treatment‑related serious adverse events were observed. The company said it will report longer‑term data later this year and expects topline results from its female‑pattern‑hair‑loss study in the first half of 2027.
Why it matters
The trial results lifted Veradermics’ share price, which rose between 6% and 10% in pre‑market trading. Management noted the company holds about $820 million in cash, giving it runway to pursue a regulatory filing and potential launch.
Key facts
- 1The Phase 3 Study 304 enrolled 536 male participants with mild‑to‑moderate pattern hair loss. stocktitan.net
- 2Target‑area hair count increased by 28.6 hairs/cm² for the once‑daily dose and 36.4 hairs/cm² for the twice‑daily dose, versus 6.6 hairs/cm² for placebo. tradingview.com
- 378.8% of once‑daily participants and 85.0% of twice‑daily participants reported visible improvement, compared with 35.3% for placebo. investing.com
- 4No treatment‑related serious adverse events were reported in the trial. tradingview.com
- 5Veradermics’ shares rose 6.7% in pre‑market trading after the announcement. investing.com
- 6Veradermics reported cash of approximately $820 million on its balance sheet. finance.yahoo.com
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.